Commentary: SEMA3B is associated with disease activity and infliximab response in IBD patients but does not contribute to the development of intestinal inflammation in vivo

1

SEMA3B is associated with disease activity and infliximab response in IBD, but does not directly contribute to intestinal inflammation development.
2

The study suggests SEMA3B may serve as a stratification marker rather than a standalone biomarker for predicting treatment response in IBD.
3

SEMA3B expression correlates with disease activity, but its predictive performance for infliximab response is modest, indicating broader molecular network involvement.
4

The association between SEMA3B and infliximab response may reflect a mucosal state conducive to treatment rather than a specific mechanistic role.
5

Negative findings in the DSS model suggest SEMA3B does not improve disease severity, warranting cautious interpretation of its role in inflammation.

1